In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia

被引：36

作者：

Chandenier, J ^{[1
]}

Adou-Bryn, KD

Douchet, C

Sar, B

Kombila, M

Swinne, D

Thérizol-Ferly, M

Buisson, Y

Richard-Lenoble, D

机构：

[1] Ctr Hosp & Univ, Serv Parasitol Mycol Med Trop, F-37000 Tours, France

[2] Inst Pasteur Cambodge, Phnom Penh, Cambodia

[3] FMSS, Dept Parasitol Mycol Med Trop, Libreville, Gabon

[4] Inst Sci Sante Publ Mycol, B-141050 Brussels, Belgium

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2004年 / 23卷 / 06期

关键词：

D O I：

10.1007/s10096-004-1136-2

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In order to determine the potential role that various antifungal agents might have in the management of cryptococcosis in tropical areas, the in vitro susceptibility of Cryptococcus neoformans isolates from Africa (n=52) and Cambodia (n=110) to three antifungal agents (amphotericin 13, fluconazole and voriconazole) were compared using the E-test method. The results of this study (1) confirm the value of the E-test for testing the in vitro susceptibility of C neoformans towards voriconazole; (ii) provide the first evidence demonstrating good activity of amphotericin B, fluconazole and voriconazole against Cambodian isolates; and (iii) show there are differences in susceptibility between African and Asian C neoformans isolates, with Cambodian isolates appearing less susceptible to the agents tested but with amphotericin B maintaining good activity.

引用

页码：506 / 508

页数：3

共 15 条

[1] Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States:: 1992 to 1994 and 1996 to 1998
Brandt, ME
Pfaller, MA
Hajjeh, RA
Hamill, RJ
Pappas, PG
Reingold, AL
Rimland, D
Warnock, DW
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) : 3065 - 3069
[2] Comparison of broth macrodilution, broth microdilution and E-test susceptibility tests of Cryptococcus neoformans for fluconazole
Chryssanthou, E
Gronfors, C
Khanna, N
[J]. MYCOSES, 1997, 40 (11-12) : 423 - 427
[3] In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole
Davey, KG
Johnson, EM
Holmes, AD
Szekely, A
Warnock, DW
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) : 217 - 220
[4] DOUCHET C, 1995, J MYCOL MED, V5, P122
[5] In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature
Espinel-Ingroff, A
Boyle, K
Sheehan, DJ
[J]. MYCOPATHOLOGIA, 2001, 150 (03) : 101 - 115
[6] Hoffman HL, 2002, EXPERT OPIN INV DRUG, V11, P409
[7] In vitro antifungal susceptibility testing
Hoffman, HL
Pfaller, MA
[J]. PHARMACOTHERAPY, 2001, 21 (08): : 111S - 123S
[8] Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates:: Performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies
Lozano-Chiu, M
Paetznick, VL
Ghannoum, MA
Rex, JH
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) : 2817 - 2822
[9] Evaluation of etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans
Maxwell, AJ
Messer, SA
Hollis, RJ
Diekema, DJ
Pfaller, MA
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (01) : 97 - 99
[10] CRYPTOCOCCOSIS IN THE ERA OF AIDS - 100 YEARS AFTER THE DISCOVERY OF CRYPTOCOCCUS-NEOFORMANS
MITCHELL, TG
PERFECT, JR
[J]. CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (04) : 515 - &

← 1 2 →